株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

循環腫瘍細胞 (CTC) および癌幹細胞 (CSC) の市場

The Market for Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs)

発行 Kalorama Information 商品コード 279333
出版日 ページ情報 英文 204 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
循環腫瘍細胞 (CTC) および癌幹細胞 (CSC) の市場 The Market for Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs)
出版日: 2015年06月19日 ページ情報: 英文 204 Pages
概要

当レポートは、循環腫瘍細胞(CTC)をベースとした各種技術とその可能性について調査し、癌および循環腫瘍細胞 (CTC) の概要、現在および未来のCTCマーカー、現在および未来のCTCの臨床的用途、CTCの各種分離・検出・回収技術、産業構造、市場に影響を及ぼす各種動向、企業および企業間の取り組み、用途・地域別の市場収益の推移と予測、主要企業のプロファイルなどをまとめています。

第1章 エグゼクティブサマリー

第2章 癌の概要

  • 疾病の概要
  • リスク因子
  • 有病率・発生率

第3章 循環腫瘍細胞 (CTC) の概要

  • 概要
  • CTCの用途
  • CTCの特徴
  • CTCの特定・分析のための現在のマーカー
    • EpCAM
    • EpB4
    • EGFR
    • HER2
    • MUC-1
    • CEA
    • サイトケラチン
  • 臨床用途で研究中のその他のCTCマーカー
    • シクロフィリン
    • プラスチン3
    • ビメンチン
    • 総論
  • 現在・将来のCTCの臨床用途
    • 生存予測ツール
    • 癌の非侵襲性初期診断
    • 疾患の推移・転移力の予測
    • 治療のガイダンスとモニタリング・治療効果の予測材料
    • 臨床試験における患者の層別化
    • 臨床試験における代用エンドポイント
    • 薬剤開発:薬剤標的の選定

第4章 CTC分離・検出技術

  • 概要
  • 物理特性に基づく濃縮法
    • サイズベース
    • 濃度ベース
    • 電気生理学ベース
  • 免疫仲介性の回収法
    • 免疫磁気プラットフォーム
    • マイクロ流体プラットフォーム
    • 総論
  • 光学的特定・表示
    • BioviewのDuet Cell Imaging System (イスラエル)
    • CytoTrackのOptical Scanning Technology (デンマーク)
    • Epic Sciences (米国)
    • Ikonisys (米国)
  • 核酸ベースのCTC検出法
    • RNAscope (Advanced Cell Diagnostics:米国)
  • 細胞数測定による検出・表示
    • FASTcell Cytometer (SRI Biosciences:米国)
    • On-chip Sort Cell Sorter (オンチップバイオテクノロジーズ:日本)
  • その他のCTC分離・検出技アプローチ

第5章 産業・市場情勢

  • 産業構造
  • 競合因子
  • 製品分析
    • CellSearch
    • AdnaTests
  • 主要市場動向
  • 産業における主な出来事
  • 総市場の収益とその予測
    • 市場概要
    • 総市場の予測

第6章 企業プロファイル

  • Janssen Diagnostics
  • AdnaGen AG (現QIAGEN Hannover GmbH)
  • Acousys Biodevices, Inc.
  • Advanced Cell Diagnostics, Inc.
  • ApoCell, Inc.
  • BioCEP Ltd.
  • Biocept, Inc.
  • Biofluidica
  • BioView Ltd.
  • Clearbridge Biomedics Pte Ltd
  • Creatv MicroTech, Inc.
  • Cynvenio Biosystems
  • CytoTrack ApS
  • DeNovo Sciences Inc.
  • Epic Sciences
  • Fluidigm Corporation
  • Fluxion Biosciences
  • GILUPI GmbH
  • iCellate Medical AB
  • Ikonisys, Inc.
  • IVDiagnostics, LLC
  • Miltenyi Biotec GmbH
  • On-chip Biotechnologies
  • Oncolys Biopharma Inc.
  • Parsortix/ANGLE plc
  • QIAGEN N.V.
  • RareCells Diagnostics
  • RareCyte, Inc.
  • ScreenCell
  • Silicon Biosystems
  • SRI Biosciences
  • Vitatex Inc.
  • Vortex Biosciences

図表リスト

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: KLI5593376

Circulating tumor cells (CTCs) have tremendous utility in cancer research, aiding researchers in deciphering the complex processes leading to cancer metastasis and in developing more effective cancer therapeutics. Besides the research applications, the detection and analysis of CTCs has enormous potential in the diagnosis and management of cancer, as current tools, such as tumor tissue biopsy or imaging technologies, have numerous limitations. Although their biology and characteristics are still not entirely elucidated, CTCs are believed to detach from primary or secondary tumors, enter the bloodstream, and travel to distant organs. The majority of CTCs die in the bloodstream due to the harsh environment; very few of them are able to metastasize, and even fewer - known as cancer stem cells (CSCs) - can form distant tumors. Nevertheless, this small percentage of CTCs - about 0.01% - is sufficient to initiate and continue the blood-borne metastasis process, which leads to the progression of the disease and death.

The Market for Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) is a detailed analysis of the potential opportunities for manufacturers of CTCs-based technologies, informing readers of the scientific basis of CTCs in an understandable fashion and constructing models of revenue opportunity based on several dimensions - application area, cancer type and region - that can assist with business planning efforts.

The report provides data on the following:

  • Industry Structure - Selected Competitors and Marketed Products, 2014
  • CellSearch System (IVD Use) Analysis, 2015
  • AdnaTest (IVD Use) Analysis, 2015
  • Significant Trends in the CTCs Market, 2015
  • Estimated Market Breakdown, 2014 (Research Segment, Diagnostics Segment)
  • Estimated Market Breakdown by Type of Cancer, 2014
  • Estimated Market Breakdown by Geographic Region, 2014
  • Global Revenues and Forecast for the CTCs Market by Application, 2013-2015 and 2019
  • Global Revenues for the CTCs Market by Geographic Region, 2013-2015 and 2019

The global market for technologies serving CTCs research and diagnostics is experiencing several notable trends that have a significant effect on its participants, as well as on the overall market growth. The report presents analysis of such trends, including:

  • Increasing Incorporation of CTCs Technologies in Clinical Trials to Accelerate Market Growth
  • The Quest for Personalized Medicine to Spur the Use of CTCs in Research & Development
  • Increasing Development of CTC-based Diagnostics Tests to Augment Market Revenues
  • Increasing Global Incidence of Cancer and Life Expectancy to Increase Testing Volumes
  • The Impact of Clinical Utility on Adoption of CTCs Tests in Clinical Practice
  • The Impact of New Technologies Approved by Regulatory Agencies on Market Growth
  • The Impact of Insurance Coverage on Utilization and Market Revenues

The report also covers notable industry events such as:

  • CTCs Enumeration by CellSearch Demonstrating Potential as an Efficacy-Response Surrogate
  • The Menarini Group Acquisition of Silicon Biosystems
  • Cynvenio Biosystems' Launch of the ClearID Breast Cancer Monitoring Test
  • Vitatex's Licensing of Cell Adhesion Matrix Technology to Noble Life Sciences
  • Janssen Diagnostics and Asuragen's Introduction of NGS technology for CellSearch

The global market for CTC detection, isolation and analysis devices is a heterogeneous and competitive market, constantly driven by technological innovation and demand for improved technologies. The market includes numerous competitors with different capabilities. These numerous specialized or research-based companies also develop and commercialize products for the detection, isolation and analysis of CTCs, and contribute considerably to the technological advancements in this field. As part of its extensive coverage, the report profiles several competitors in the market.

The following companies are profiled:

  • Janssen Diagnostics
  • AdnaGen AG (currently QIAGEN Hannover GmbH)
  • Acousys Biodevices, Inc.
  • Advanced Cell Diagnostics, Inc.
  • ApoCell, Inc.
  • BioCEP Ltd.
  • Biocept, Inc.
  • Biofluidica
  • BioView Ltd.
  • Clearbridge Biomedics Pte Ltd
  • Creatv MicroTech, Inc.
  • Cynvenio Biosystems
  • CytoTrack ApS
  • DeNovo Sciences Inc.
  • Epic Sciences
  • Fluidigm Corporation
  • Fluxion Biosciences
  • GILUPI GmbH
  • iCellate Medical AB
  • Ikonisys, Inc.
  • IVDiagnostics, LLC
  • Miltenyi Biotec GmbH
  • On-chip Biotechnologies
  • Oncolys Biopharma Inc.
  • Parsortix/ANGLE plc
  • QIAGEN N.V.
  • RareCells Diagnostics
  • RareCyte, Inc.
  • ScreenCell
  • Silicon Biosystems
  • SRI Biosciences
  • Vitatex Inc.
  • Vortex Biosciences

Table of Contents

ONE: EXECUTIVE SUMMARY

  • Circulating Tumor Cells in Cancer
  • Current and Potential Clinical Applications of CTCs
  • CTCs Detection, Isolation and Analysis Technologies
  • Industry and Market Structure

TWO: CANCER OVERVIEW

  • Disease Overview
  • Risk Factors
  • Prevalence and Incidence of Cancer

THREE: CIRCULATING TUMOR CELLS OVERVIEW

  • Overview
  • CTCs Applications
  • Characteristics of CTCs
  • CTCs Isolation and Characterization Challenges
  • Current Markers for CTCs Identification and Analysis
  • Epithelial Cell Adhesion Molecule (EpCAM)
  • Ephrin Receptor B4 (EpB4)
  • Epidermal Growth Factor Receptor (EGFR)
  • Human Epidermal Growth Factor (HER2)
  • Mucin-1 (MUC-1)
  • Carcinoembryonic Antigen (CEA)
  • Cytokeratins
  • Other CTCs Markers Investigated for Clinical Applications
  • Cyclophilins
  • Plastin3 (PLS3)
  • Vimentin
  • Conclusions
  • Current and Potential Clinical Applications of CTCs
  • Prognostic Tool for Survival
  • Non-Invasive Early Diagnosis of Cancer
  • Predictors of Disease Evolution and Metastatic Potential
  • Therapy Guidance and Monitoring/ Predictor of Response to Therapy
  • Patient Stratification in Clinical Trials
  • Surrogate Endpoint in Clinical Trials
  • Drug Development - Selection of Drug Targets

FOUR: CTCs ISOLATION AND DETECTION TECHNOLOGIES

  • Overview
  • Enrichment Methods Based on Physical Properties
  • Size-based Methods
  • Density-based Methods
  • Electrophysiological-based Methods
  • Immuno-Mediated Capture Methods
  • Magnetic Platforms
  • Microfluidic Platforms
  • Conclusion
  • Optical Identification and Enumeration
  • Bioview's Duet Cell Imaging System (Israel)
  • CytoTrack's Optical Scanning Technology (Denmark)
  • Epic Sciences (San Diego, California, USA)
  • Ikonisys (New Haven, CT, USA)
  • Nucleic Acid-based CTC Detection Methods
  • RNAscope (Advanced Cell Diagnostics, USA)
  • Cytometric Detection and Enumeration Methods
  • FASTcell Cytometer (SRI Biosciences, USA)
  • On-chip Sort Cell Sorter (On-chip Biotechnologies, Japan)
  • Other CTCs Isolation and Detection Approaches
  • Virus Vectors Fluorescence
  • Selectin-Mediated Capture
  • Cell Adhesion Matrix
  • Other Combination Negative Depletion/ Positive Selection Methods
  • Rheology-based Methods
  • In Vivo Detection Methods

FIVE: INDUSTRY AND MARKET LANDSCAPE

  • Industry Structure
  • Competitive Factors
  • Products Analysis
  • CellSearch
  • AdnaTests
  • Significant Market Trends
  • Increasing Incorporation of CTCs Technologies in Clinical Trials to Accelerate
  • Market Growth
  • The Quest for Personalized Medicine to Spur the Use of CTCs in Research & Development
  • Increasing Development of CTC-based Diagnostics Tests to Augment Market Revenues
  • Increasing Global Incidence of Cancer and Life Expectancy to Increase Testing Volumes
  • The Impact of Clinical Utility on Adoption of CTCs Tests in Clinical Practice
  • The Impact of New Technologies Approved by Regulatory Agencies on Market Growth
  • The Impact of Insurance Coverage on Utilization and Market Revenues
  • Notable Industry Events
  • CTCs Enumeration by CellSearch Demonstrated Potential as Efficacy-Response Surrogate
  • The Menarini Group Acquired Silicon Biosystems
  • Cynvenio Biosystems Launched ClearID Breast Cancer Monitoring Test
  • Vitatex Licenses Cell Adhesion Matrix Technology to Noble Life Sciences
  • SWOG S0500 Clinical Trial Results Presented in December 2013
  • Parsorter PS1 Launched to Market in Europe
  • Clearbridge Biomedics Launched the ClearCell FX System for Capturing CTCs in Whole Blood Samples
  • Fluxion Biosciences Launched Next Generation Sequencing Assay Kits for IsoFlux System
  • Janssen Diagnostics and Asuragen Introduce NGS technology for CellSearch
  • Biocept Collaborates with Rosetta Genomics to Evaluate CTCs' microRNA
  • Biocept Launches Lung Cancer CTC Tests
  • Parsortix Collaborates with EKF Diagnostics and Undisclosed Pharmaceutical
  • Company to Develop “Liquid Biopsy” Applications
  • ThermoFisher Scientific Enters into Distribution Agreement with Cynvenio
  • Biosystems for LiquidBiopsy Platform
  • QIAGEN Acquired AdnaGen's CTC's Technology
  • Total Market Revenues and Forecast
  • Market Snapshot
  • Total Market Forecast

SIX: COMPANY PROFILES

  • Janssen Diagnostics
  • AdnaGen AG (currently QIAGEN Hannover GmbH)
  • Acousys Biodevices, Inc.
  • Advanced Cell Diagnostics, Inc.
  • ApoCell, Inc.
  • BioCEP Ltd.
  • Biocept, Inc.
  • Biofluidica
  • BioView Ltd.
  • Clearbridge Biomedics Pte Ltd
  • Creatv MicroTech, Inc.
  • Cynvenio Biosystems
  • CytoTrack ApS
  • DeNovo Sciences Inc.
  • Epic Sciences
  • Fluidigm Corporation
  • Fluxion Biosciences
  • GILUPI GmbH
  • iCellate Medical AB
  • Ikonisys, Inc.
  • IVDiagnostics, LLC
  • Miltenyi Biotec GmbH
  • On-chip Biotechnologies
  • Oncolys Biopharma Inc.
  • Parsortix/ANGLE plc
  • QIAGEN N.V.
  • RareCells Diagnostics
  • RareCyte, Inc.
  • ScreenCell
  • Silicon Biosystems
  • SRI Biosciences
  • Vitatex Inc.
  • Vortex Biosciences

LIST OF EXHIBITS

TWO: CANCER OVERVIEW

  • Table 2-1: Top Ten Causes of Death in the World by Geographic Region, 2012
  • Table 2-2: Top Ten Causes of Death in the World, 2012
  • Table 2-3: Projected Top Ten Causes of Death in the World, 2015
  • Table 2-4: Projected Top Ten Causes of Death in the World in High Income Countries, 2015
  • Table 2-5: Projected Top Ten Causes of Death in the World in Upper Middle Income Countries, 2015
  • Table 2-6: Global Incidence of Cancer by Geographic Region, 2012
  • Table 2-7: Global Incidence of the Five Most Common Types of Cancer in Men,2012
  • Table 2-8: Global Incidence of the Five Most Common Types of Cancer in Women, 2012
  • Table 2-9: Global Incidence of Most Common Types of Cancer in Both Genders,2012
  • Table 2-10: Projected Growth in Global Incidence of Cancer by Geographic Region, 2012-2030

THREE: CIRCULATING TUMOR CELLS OVERVIEW

  • Table 3-1: Typical Human Blood Cellular Composition
  • Table 3-2: Challenges in the Detection and Isolation of CTCs, 2015
  • Table 3-3: Selected Markers for CTCs Identification and Analysis
  • Table 3-4: Selected EpCAM-based Methods
  • Table 3-5: Current and Potential Clinical Uses of CTCs, 2015

FOUR: CTCs ISOLATION AND DETECTION TECHNOLOGIES

  • Table 4-1: Selected Size-Based CTCs Enrichment Methods
  • Table 4-2: Selected Density-Based CTCs Enrichment Methods
  • Table 4-3: Selected CTCs Detection and Isolation Methods Based on Electrophysiological Properties
  • Table 4-4: Selected CTCs Magnetic Platforms Based on Cell Surface Markers
  • Table 4-5: Selected CTCs Immunomagnetic Microfluidics Platforms
  • Table 4-6: Selected CTCs Optical Identification Methods
  • Table 4-7: Selected Nucleic Acid-based CTCs Detection Methods
  • Table 4-8: Comparison of Selected Cytometric CTCs Detection Methods
  • Table 4-9: Selected CTCs In Vivo Detection Platforms

FIVE: INDUSTRY AND MARKET LANDSCAPE

  • Table 5-1: Industry Structure - Selected Competitors and Marketed Products, 2014
  • Table 5-2: CellSearch System (IVD Use) Analysis, 2015
  • Table 5-3: AdnaTest (IVD Use) Analysis, 2015
  • Table 5-4: Significant Trends in the CTCs Market, 2015
  • Figure 5-1: Estimated Market Breakdown, 2014 (Research Segment, Diagnostics Segment)
  • Figure 5-2: Estimated Market Breakdown by Type of Cancer, 2014 (Breast, Prostate, Colorectal, Lung, Others)
  • Figure 5-3: Estimated Market Breakdown by Geographic Region, 2014 (US, EU, ROW)
  • Table 5-5: Global Revenues and Forecast for the CTCs Market by Application, 2013-2015 and 2019 (Diagnostics Segment, Research Segment, Total Market)
  • Figure 5-4: Global Revenues and Forecast for the CTCs Market, 2013-2015 and 2019 (Diagnostics Segment, Research Segment, Total Market)
  • Table 5-6: Global Revenues for the CTCs Market by Geographic Region, 2013-2015 and 2019 (US Market, EU Market, ROW Market, Total Market)
  • Figure 5-5: Global Revenues for the CTCs Market by Geographic Region, 2013- 2015 and 2019 (US Market, EU Market, ROW Market, Total Market)
Back to Top